Efficacy and Safety of Ravagalimab in Patients with Moderate-to-Severe Ulcerative Colitis: Data from a Phase 2a Trial.

Peyrin-Biroulet L, Seenan JP, Armuzzi A, Lazar A, Eldred A, Doan T, Polakow SB, Al Mahi N, Liu M, Nader A, Bhatnagar S, Schreiber S

Open source

DOI: 10.1007/s12325-026-03517-3
Published: 2026 Jun
Container: Advances in therapy
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s12325-026-03517-3,
  title = {Efficacy and Safety of Ravagalimab in Patients with Moderate-to-Severe Ulcerative Colitis: Data from a Phase 2a Trial.},
  author = {Peyrin-Biroulet L and Seenan JP and Armuzzi A and Lazar A and Eldred A and Doan T and Polakow SB and Al Mahi N and Liu M and Nader A and Bhatnagar S and Schreiber S},
  year = {2026},
  journal = {Advances in therapy},
  doi = {10.1007/s12325-026-03517-3},
  url = {https://doi.org/10.1007/s12325-026-03517-3}
}

RIS

TY  - JOUR
TI  - Efficacy and Safety of Ravagalimab in Patients with Moderate-to-Severe Ulcerative Colitis: Data from a Phase 2a Trial.
AU  - Peyrin-Biroulet L
AU  - Seenan JP
AU  - Armuzzi A
AU  - Lazar A
AU  - Eldred A
AU  - Doan T
AU  - Polakow SB
AU  - Al Mahi N
AU  - Liu M
AU  - Nader A
AU  - Bhatnagar S
AU  - Schreiber S
PY  - 2026
JO  - Advances in therapy
DO  - 10.1007/s12325-026-03517-3
UR  - https://doi.org/10.1007/s12325-026-03517-3
ER  -

APA

L, P., JP, S., A, A., A, L., A, E., T, D., SB, P., N, A. M., M, L., A, N., S, B., & S, S. (2026). Efficacy and Safety of Ravagalimab in Patients with Moderate-to-Severe Ulcerative Colitis: Data from a Phase 2a Trial.. Advances in therapy. https://doi.org/10.1007/s12325-026-03517-3

Source records

pubmed · retrieved 2026-09-26T15:50:58.657Z